Request Demo

Last update 15 Jul 2025

Fentanyl

Last update 15 Jul 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryFentanyl is a synthetic opioid that is highly effective in the management of severe pain, especially in cancer patients. It exerts its analgesic effects by binding to opioid receptors in the central nervous system. Fentanyl is available in various formulations, including transdermal patches, lozenges, and injectable solutions. However, due to its potency, fentanyl carries a high risk of addiction, respiratory depression, and overdose. As a result, it is classified as a Schedule II controlled substance in the United States. Ongoing research is focused on developing safer and more effective delivery methods for fentanyl, such as abuse-deterrent formulations and novel routes of administration.

Drug Type

Small molecule drug

Synonyms

AeroLEF, Fentany Transdermal System, Fentanyl (JAN/USP/INN)

+ [38]

Target

Opioid receptors

Action

agonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesNeoplasms

Active Indication

Cancer PainChronic PainPain+ [4]

Inactive Indication

Acute PainAdvanced cancerBreakthrough Pain+ [11]

Originator Organization

Janssen Global Services LLC

Active Organization

Medrx Co., Ltd.Janssen Pharmaceutical KK

Beijing Kenuo Medical Technology Co., Ltd.

+ [6]

Inactive Organization

INSYS Therapeutics, Inc.

Janssen Pharmaceuticals, Inc.Janssen-Cilag GmbH

+ [4]

License Organization

Terumo Corp. /Hemodialyzer Marketing Operations/

Nutriband, Inc.

Kindeva Drug Delivery LP

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (07 Aug 1990),

HypoventilationPain, Postoperative

Regulation-

Structure/Sequence

Molecular FormulaC22H28N2O

InChIKeyPJMPHNIQZUBGLI-UHFFFAOYSA-N

CAS Registry437-38-7

808

Clinical Trials associated with Fentanyl

NCT06953453

/ Not yet recruitingPhase 1

A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Malignant Tumors

This study is a single-dose, open-label, 2-cycle crossover design, comparing the pharmacokinetic parameters and safety of Inhaled Fentanyl Aerosol and intravenous fentanyl injection.

Start Date30 Aug 2025

Sponsor / Collaborator

Lee's Pharmaceutical Holdings Ltd.

NCT06793358

/ Not yet recruitingPhase 4IIT

Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

The goal of this clinical trial is to learn if a combination of the two established sedation drugs remimazolam and fentanyl, can put the subject to sleep during a scheduled extraction procedure. The combined use of these drugs has been used in other studies involving IV sedation when the procedure is scheduled for 30 minutes or less. However, the combined use of the IV sedation drugs has not been used in a dental extraction procedure before.
The main questions it aims to answer are:
1. Can the combined drugs effectively put the patient to sleep during the procedure
2. How quickly will they come out of the sedation after the procedure
Participants will:
1. Receive the combined drugs during a scheduled extraction procedure anticipated to take less than 30 minutes
2. Answer survey questions related to their study experience after the extraction visit (in person) and again about 24 hours after the visit (by telephone).

Start Date31 Jul 2025

Sponsor / Collaborator

Indiana University

[+1]

NCT06696586

/ Not yet recruitingPhase 4IIT

Comparison Between Effect of Systemic Fentanyl Infusion and Fentanyl Added as An Adjuvant to Lidocaine in Bier Block For Controlling Pain in Patients Undergoing Hand Surgeries

Injury and deformity of the upper extremity can result in dysfunction to nerves, tendons and bones which can lead to disability and pain.
Various techniques of regional anesthesia are frequently used for upper extremity surgery. Specifically, intravenous regional anesthesia, the Bier block, is an effective anesthetic technique. This technique, developed by Dr August Bier in 1908, provides complete anesthesia, a bloodless field, and eliminates the need for general anesthesia. However, it was not until the 1960s that this technique was reintroduced and used in upper extremity surgery due to several disadvantages and reports of major complications. Because of the dose of lidocaine and tourniquet time, there is potential for cardiac and neurological complications such as arrhythmias, seizures, and compartment syndrome the aim of this study To evaluate the effect of Systemic Fentanyl Infusion compared to addition of Fentanyl as An Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries

Start Date01 Jul 2025

Sponsor / Collaborator

Assiut University

100 Clinical Results associated with Fentanyl

100 Translational Medicine associated with Fentanyl

100 Patents (Medical) associated with Fentanyl

30,240

Literatures (Medical) associated with Fentanyl

31 Dec 2025·ANNALS OF MEDICINE

Respiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial

Article

Author: Chen, Huihe ; Luo, Jiaxin ; Guan, Xuehai ; Wu, Xiaoshan ; Cao, Huiyu ; Lan, Hongmeng ; Lin, Yuliu ; Zhang, Cuiwen ; Liao, Yeqing ; Huang, Xiaofang

BACKGROUND:

A combination of opioids with propofol is a popular approach to non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression. We compared the incidence of esketamine- and fentanyl-induced respiratory depression in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.

METHODS:

This study included 176 women (aged 18-60 years) scheduled for abortion surgery or curettage. Patients were randomized into the fentanyl or esketamine groups. Patients in the fentanyl group received fentanyl (1 µg/kg) combined with propofol intravenously. Patients in the esketamine group received subanaesthetic doses of esketamine (0.15 mg/kg) combined with propofol intravenously. The primary outcome was the incidence of respiratory depression during anaesthesia. Secondary outcomes included respiratory rate, pulse oximetry, blood pressure, heart rate, propofol dose, duration of surgery, duration of anaesthesia, and adverse events.

RESULTS:

The incidence of respiratory depression in the esketamine group was significantly lower than that in the fentanyl group (11% vs. 45%; p < .0001). Propofol administration was lower with esketamine than fentanyl. Respiratory rate, SpO₂ and blood pressure were more stable in the esketamine group than in the fentanyl group. The incidences of hypotension, propofol-induced injection pain and chin lifting in the esketamine group were lower than those in the fentanyl group. The incidence of nightmares was higher in the esketamine than in the fentanyl group.

CONCLUSIONS:

The incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.KEY MESSAGESOpioids combined with propofol is a popular method for non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression.At subanaesthetic doses, esketamine provides an analgesic effect by antagonizing the N-methyl-d-aspartate receptor.In this trial, the incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.

01 Nov 2025·NEUROPHARMACOLOGY

Perinatal fentanyl exposure drives enduring addiction risk and central amygdala gene dysregulation

Article

Author: Telese, Francesca ; Palmer, Abraham A ; Shin, Yeji ; Balaguer, Maria G ; Wood, Courtney P ; Dirik, Selen ; Campo, Paola ; Montoya, Bryan A ; Naghshineh, Parsa K ; de Guglielmo, Giordano ; Cook, Gregory M R ; Palermo, Gabrielle M ; Morgan, Alex ; Rahman, Sara R M U

The use of fentanyl and other opioids during pregnancy is a pressing public health issue due to its association with Neonatal Opioid Withdrawal Syndrome (NOWS) and long-term neurobehavioral deficits. Human epidemiologic studies are confounded by both genetic and environmental factors that differ between exposed and unexposed children. We developed a novel rat model of perinatal fentanyl exposure in heterogeneous stock (HS) rats characterized by high genetic diversity, to investigate NOWS symptoms and its long-term effects on adult fentanyl self-administration, drug-seeking behavior, and central amygdala (CeA) transcriptomic changes, addressing a critical gap in understanding synthetic opioid impacts. Offspring born to fentanyl-exposed dams exhibited reduced survival, lower body weight, spontaneous withdrawal symptoms, and mechanical hypersensitivity during adolescence. These rats displayed negative affect in adolescence, while they showed increased fentanyl self-administration, heightened drug-seeking during reinstatement, and elevated corticosterone levels during withdrawal in adulthood. To explore the molecular underpinnings of these physiological and behavioral outcomes, we conducted RNA-seq in the CeA of adult rats, revealing dysregulated pathways related to GPCR signaling, adaptive immune response and neurodevelopmental processes. These transcriptional changes provide insights into the mechanisms driving addiction vulnerability and stress-related behaviors following early fentanyl exposure. Our findings highlight the lasting impact of perinatal opioid exposure in an experimental system that avoids many of the confounds that plague studies in humans, underscoring the need for preclinical models to study NOWS and its long-term consequences. This model offers translational relevance for developing therapeutic strategies to mitigate NOWS and reduce neuropsychiatric risks associated with perinatal opioid exposure.

01 Nov 2025·NEUROPHARMACOLOGY

Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption

Article

Author: Wolf, Kayla J ; Pressley, Justin M ; Moran, Jeffery H ; Fantegrossi, William E ; Gannon, Brenda M ; Shaw, Hannah E ; Shepard, Mary E ; Avram, Marina

Oral use of illicit fentanyl formulations is common, and these preparations may be contaminated with fentanyl analogs (FAs) with unknown pharmacological and toxicological properties. Route of administration impacts pharmacological effects, and pharmacokinetic or pharmacodynamic properties of oral fentanyl and FAs could influence aspects of opioid use disorder that are not necessarily present in animal models involving other routes of administration. We established oral consumption of water, or solutions of the FAs furanyl fentanyl and acryl fentanyl in C57 B l/6N mice. Consumption of pharmacologically-relevant concentrations of the FAs was reliably engendered, verified by induction of opioid-mediated antinociceptive effects in a warm-water tail withdrawal procedure, hypothermic effects, and observation of antagonist-precipitated withdrawal. When maintenance solutions were adulterated with the bitter tastant quinine, water control mice decreased their consumption, but mice consuming FA solutions defended their consumption, even at quinine concentrations that suppressed water drinking. Brief access to supplemental water, injection of the μ-opioid antagonist naltrexone, or administration of the μ-opioid agonist morphine all attenuated the defense of FA consumption. In all cases, the abuse-related effects of acryl fentanyl were greater than those of furanyl fentanyl. Consumption of acryl fentanyl also abolished weight gain across the study, and disrupted nest-building. The results of these experiments suggest that mice drinking furanyl fentanyl or acryl fentanyl experience opioid-mediated effects including antinociception, dependence and withdrawal, and abuse-related subjective effects, and provide proof of concept for use of this model to assess pharmacological and non-pharmacological manipulations which may attenuate the reinforcing effects of oral fentanyl and FAs.

397

News (Medical) associated with Fentanyl

19 Jun 2025

·www.prnewswire.com

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl use1 Additional Indivior-funded research identified OUD treatment barriers in American Indian/Alaska Native (AI/AN) people who are often affected by higher drug overdose death rates compared to other racial and ethnic groups2-5 RICHMOND, Va., June 19, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting. A post hoc analysis showed that patients with heavier fentanyl use experienced clinically meaningful improvements in opioid abstinence when treated with a 300 mg maintenance dose of SUBLOCADE, compared to the 100 mg dose. While the 300 mg dose did not demonstrate a statistically significant advantage over 100 mg for weekly abstinence—the study's primary endpoint—in the overall population with moderate to severe opioid use disorder (OUD), the results suggest that higher doses of SUBLOCADE may offer better outcomes for individuals with high levels of fentanyl use. "These findings offer additional evidence that the higher maintenance dose of SUBLOCADE is safe and may better support patients with intense fentanyl use patterns," said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. "We aim to provide clinicians with new data that can transform treatment strategies and support patients on their journey to recovery." In the Indivior-funded study, patients with OUD who engaged in high-risk opioid use—such as injection use, high opioid dose consumption, or fentanyl use—received two initial 300 mg injections of SUBLOCADE one week apart. They were then randomized to receive eight monthly maintenance doses of either 100 mg or 300 mg. Both dosing regimens led to significant reductions in opioid use: the average weekly use dropped sharply from over 40 instances at screening to fewer than 3 by Week 3, and this improvement was sustained through Week 38. Notably, no new safety concerns were identified with either the 100 mg or 300 mg maintenance doses. Indivior also funded research exploring OUD treatment access and outcomes in American Indian/Alaska Native (AI/AN) populations, which were presented at CPDD. AI/AN populations experience disproportionate rates of OUD, drug overdose, and gap in access to OUD care. A thematic analysis of focus group research on nine AI/AN advocates indicated that AI/AN people experience significant barriers to accessing medication for opioid use disorder (MOUD).4-8 Barriers include stigma, institutional challenges, and transitions of care for OUD, highlighting opportunities for culturally appropriate interactive education and institutional advancement.2 These focus group findings are illustrative and can be used to identify avenues for future work, although they may not be generalizable to the full population. In addition, a large multi-year longitudinal claims database analysis of more than 75,000 AI/AN patients with evidence of OUD showed differences in utilization of MOUD among those seeing Indian Health Services (IHS) vs. non-IHS providers. The majority of patients (73.1%) saw non-IHS providers. Patients treated with any form of MOUD had lower all-cause emergency department vs. those who were not treated with MOUD, highlighting the need for further research to understand MOUD utilization among AI/AN. "The collective evidence from these presentations highlights prominent barriers to effective care and helps map out appropriate treatment approaches for individuals with OUD in challenging treatment settings," said Heidbreder. "Indivior focuses its scientific, treatment, and policy efforts on helping patients access the medications and support they need to recover." Key Abstracts Presented at CPDD: Higher Exposures with 300-Mg Buprenorphine Extended-Release (BUP-XR) Increased the Proportion of Responders Among Opioid Use Disorder (OUD) Patients with Heavy Fentanyl Use Barriers to and Facilitators of Medication Treatment for Opioid Use Disorder Identified by American Indian/Alaska Native Advocates Utilization of Medications for Opioid Use Disorder (MOUD) and Patient Profiles Amongst American Indian/Alaska Native Managing Opioid Use Disorder (OUD) Polysubstance Use in Treatment for Opioid Use Disorder: Opioid Abstinence and Alternative Substance Use Clinical Outcomes and Recovery in Adults with Opioid Use Disorder: Long-term Treatment with Long- acting Injectable Buprenorphine under Real-World Conditions Severity and Symptomatology of Opioid Use Disorder (OUD) Among Individuals Reporting Pain Reliever Use, Pain Reliever Misuse, and/or Heroin Use: A Cross-sectional Analysis of the 2021 and 2022 National Survey on Drug Use and Health Disclosure: This press release has been issued by Indivior Inc. and the content has not been approved or authorized by the College on Problems of Drug Dependence. About SUBLOCADE® SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. CONTRAINDICATIONS Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis. Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE. Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. ADVERSE REACTIONS Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit . About Opioid Use Disorder (OUD) Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting . Higher Exposures with 300-Mg Buprenorphine Extended-Release (BUP-XR) Increased the Proportion of Responders Among Opioid Use Disorder (OUD) Patients with Heavy Fentanyl Use [Late Breaking Oral Sessions]. CPDD Annual Scientific Meeting, June 15, 2025. Barriers To and Facilitators Of Medication Treatment for Opioid Use Disorder Identified by American Indian/Alaska Native Advocates [Oral Session: Expanding SUD interventions across populations]. CPDD Annual Scientific Meeting, June 17, 2025. Utilization of Medications for Opioid Use Disorder (MOUD) and Patient Profiles amongst American Indian/Alaska Native Managing Opioid Use Disorder (OUD) [Poster Session 1]. CPDD Annual Scientific Meeting, June 15, 2025. Indian Health Service. Disparities. 2019. Retrieved from . Accessed: 16 May 2024. Centers for Disease Control and Prevention, National Center for Health Statistics (2024). Rate of National Drug Overdose Deaths, By Demographic. Available at: statistics/overdose-death-rates. Accessed: 6 Jun 2024. Soto C, et al. (2022). International Journal of Environmental Research and Public Health, 19(5), 2974. doi:10.3390/ijerph19052974 Krawczyk N, et al. . Drug Alcohol Depend. 2021 Mar 1;220:108512. doi: 10.1016/j.drugalcdep.2021.108512 Mpofu, E, et al.. (2021). Addictive Behaviors, 114, 106743. doi:10.1016/j.addbeh.2020.106743 SOURCE Indivior PLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3

19 Jun 2025

·pharma.economictimes.indiatimes.com

Purdue Pharma's $7B opioid settlement could advance soon after states back it

OxyContin maker Purdue Pharma 's latest plan to settle thousands of lawsuits over the toll of opioids could soon move forward after every U.S. state involved agreed to it. A judge on Wednesday said he planned to issue a ruling on Friday on a plan for local governments and individual victims to vote on it. Government entities, emergency room doctors, insurers, families of children born into withdrawal from the powerful prescription painkiller, individual victims and their families and others would have until Sept. 30 to vote on whether to accept the deal, which calls for members of the Sackler family who own the company to pay up to $7 billion over 15 years. The settlement is a way to avoid trials with claims from states alone that total more than $2 trillion in damages. Thousands of local governments and other groups have also sued Purdue. Every state but Oklahoma is involved in the case. Oklahoma reached a separate settlement with Purdue in 2019. If approved, the settlement would be among the largest in a wave of lawsuits over the past decade as governments and others sought to hold drugmakers, wholesalers and pharmacies accountable for the opioid epidemic that started rising in the years after OxyContin hit the market in 1996. The other settlements together are worth about $50 billion, and most of the money is to be used to combat the crisis. In the early 2000s, most opioid deaths were linked to prescription drugs, including OxyContin. Since then, heroin and then illicitly produced fentanyl became the biggest killers. In some years, the class of drugs was linked to more than 80,000 deaths, but that number dropped sharply last year. The request of U.S. Bankruptcy Court Judge Sean Lane comes about a year after the U.S. Supreme Court rejected a previous version of Purdue's proposed settlement. The court found it was improper that the earlier iteration would have protected members of the Sackler family from lawsuits over opioids, even though they themselves were not filing for bankruptcy protection. Under the reworked plan hammered out with lawyers for state and local governments and others, groups that don't opt in to the settlement would still have the right to sue members of the wealthy family whose name once adorned museum galleries around the world and programs at several prestigious U.S. universities. Under the plan, the Sackler family members would give up ownership of Purdue. They resigned from the company's board and stopped receiving distributions from its funds before the company's initial bankruptcy filing in 2019. The remaining entity would get a new name, and its profits would be dedicated to battling the epidemic. Most of the money would go to state and local governments to address the nation's addiction and overdose crisis, but potentially more than $850 million would go directly to individual victims. That makes it different from the other major settlements. The payouts would not begin until after a hearing scheduled for Nov. 10, during which Lane is to be asked to approve the entire plan if enough of the affected parties agree. This story has been corrected to show that 49 states have agreed to the deal, not 50. Oklahoma is not involved because it reached a separate settlement previously.

Patent Infringement

19 Jun 2025

·pharma.economictimes.indiatimes.com

Purdue Pharma's $7B opioid settlement could advance soon after states back it

Patent Infringement

100 Deals associated with Fentanyl

External Link

KEGG	Wiki	ATC	Drug Bank
D00320	Fentanyl	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Janssen Pharmaceutical KK	01 Feb 2011
Pain	Australia	Janssen-Cilag Pty Ltd.	23 Nov 2005
Acute Pain	United States	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Chronic Pain	United States	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Hypoventilation	United States	Janssen Pharmaceuticals, Inc.	07 Aug 1990
Pain, Postoperative	United States	Janssen Pharmaceuticals, Inc.	07 Aug 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mucositis	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Solid tumor	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Stomatitis	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Low Back Pain	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Osteoarthritis	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Complex Regional Pain Syndromes	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Neuralgia, Postherpetic	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Pain Disorder	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Neoplasms	Phase 3	Canada	INSYS Therapeutics, Inc.	01 Dec 2007
Neoplasms	Phase 3	India	INSYS Therapeutics, Inc.	01 Dec 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Acute Pain \| Anemia, Sickle Cell	-	Intranasal Fentanyl (INF)	wqamhupjlb(gbuueuepcl) = 7 (18%) of visits pyjxseaoll (pwomolwnhr ) View more	-	08 Dec 2024
NCT05244226 (CTgov)	Phase 2	Sleep Apnea, Obstructive \| Tonsillitis \| Pain, Procedural	66	Hydromorphone+Fentanyl	sjbhojtlgu(qlmnlxvdal) = egrxrnyjpi bmqevznkhx (hyeoleraum, ayaipuyudt - bqpfzkkdsz) View more	-	17 Oct 2024
NCT03872700 (CTgov)	Phase 3	Abscess	49	Intranasal fentanyl (Intranasal Fentanyl)	zeidnufwsc(bqwcnwrnqc) = uiocjtbqce ocriusflve (uhiayapbjq, 1.5) View more	-	15 Aug 2023
				Placebo (Placebo)	zeidnufwsc(bqwcnwrnqc) = qnyhlsafnw ocriusflve (uhiayapbjq, 2.9) View more
ICML2023	Not Applicable	18 FDG	-	Fentanyl pre-treatment	ggclaulgvj(npcwzqkbkd) = hhpscuxdzk drewnazezd (vcksgykzvl )	Positive	09 Jun 2023
				No fentanyl pre-treatment	ggclaulgvj(npcwzqkbkd) = dkilsgreri drewnazezd (vcksgykzvl )
P12-11.015 (AAN2023)	Not Applicable	Parkinson Disease	1,581	Fentanyl patch	wuyizoiwbf(asqciwupfq) = involuntary, nonsuppressible writhing motion of the face, trunk and all limbs fsqjpoxmen (galjxxkqoy ) View more	Negative	25 Apr 2023
Pubmed \| Braz J Anesthesiol	Not Applicable	Anesthesia	-	Spinal fentanyl	aynvxpyroi(nkfcdqmzye) = ymspmuttuj bqcwwieyzw (gsyucourwk )	-	01 Mar 2023
				Spinal sufentanil	aynvxpyroi(nkfcdqmzye) = cibtycrjaq bqcwwieyzw (gsyucourwk )
NCT00580489 (CTgov)	Not Applicable	Pain \| Drug-Related Side Effects and Adverse Reactions	204	fentanyl+morphine (Arm C Morphine)	duxfczgtdx = aybdjviden bgmvzxukhz (abxucpvjke, ijvfvhpmpj - wupbdxheeo)	-	16 Aug 2022
				fentanyl+morphine (Arm D Fentanyl)	duxfczgtdx = ivkvlxxbig bgmvzxukhz (abxucpvjke, jrimmqutar - jmxdaxflet)
NCT03776838 (NOLGYN, Pubmed \| Anaesth Crit Care Pain Med)	Phase 4	-	70	NOL-guided administration of fentanyl	byvtwdpsbx(vaqkhuawpp) = xrkkpmucss ezrtvacwcu (wznbyjquwh, 99.9 - 113.4)	Positive	25 May 2022
				intravenous fentanyl (Standardized care)	byvtwdpsbx(vaqkhuawpp) = qkfvktkxmf ezrtvacwcu (wznbyjquwh, 97.5 - 110.7)
NCT03792191 (CTgov)	Not Applicable	Anesthesia \| Obesity	280	Lumbar Spinal Ultrasonography+Intrathecal Fentanyl+Intrathecal Bupivacaine (Ultrasonography)	yylctugfor(jhtujqkzbo) = nwrrcndeou gxuwztssyo (vsjfbmywyo, fmpkjfsmdv - gbkwnoygym) View more	-	24 May 2021
				Conventional Landmark Palpation+Intrathecal Fentanyl+Intrathecal Bupivacaine (Palpation)	yylctugfor(jhtujqkzbo) = qsmowxgycm gxuwztssyo (vsjfbmywyo, patgvaulka - vngtmnsnul) View more
NCT02514252 (CTgov)	Phase 2	Breakthrough Pain \| Advanced cancer	6	Study Diary+Fentanyl	oeumlutdtt(qmwtmljebb) = uwpvgtdfws zuejhwrnhf (hwsnigghnf, blhdaybxjr - omzlbqaoyp) View more	-	18 May 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis